Drug profile

The FDA adverse-event record for Hydrocodone Bitartrate + Homatropine Methylbromide

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Hydrocodone Bitartrate + Homatropine Methylbromide. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
17.6%
death-coded share
Dog
most-reported species
4
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
3
Deaths Reported
17.6%
Death Rate

Active Ingredients

Hydrocodone Bitartrate + Homatropine Methylbromide

Administration Routes

UnknownOral

Species Affected

Dog 17

Most Affected Breeds

Retriever - Labrador 3
Spitz - German Pomeranian 2
Terrier - Yorkshire 2
Terrier - Rat 1
Spaniel - King Charles Cavalier 1
Greater Swiss Mountain Dog 1
Sheepdog - Shetland 1
Chihuahua 1
Corgi - Welsh Cardigan 1
Shih Tzu 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Vomiting 4
Behavioural disorder NOS 3
Diarrhoea 3
Abnormal radiograph finding 3
Decreased appetite 3
Elevated alanine aminotransferase (ALT) 3
Elevated serum alkaline phosphatase (ALP) 3
Death 2
Ataxia 2
Pacing 2
Pale mucous membrane 2

Outcome Breakdown

Ongoing
5 (29.4%)
Outcome Unknown
5 (29.4%)
Recovered/Normal
4 (23.5%)
Died
2 (11.8%)
Euthanized
1 (5.9%)

Hydrocodone Bitartrate + Homatropine Methylbromide Adverse Event Insights

17 reports name Hydrocodone Bitartrate + Homatropine Methylbromide; 3 recorded a death outcome (17.6% of reported events, not a population-level mortality rate). Active ingredient: Hydrocodone Bitartrate + Homatropine Methylbromide. Administration routes: Unknown, Oral.

By species: Dog (17 reports). By breed: Retriever - Labrador (3), Spitz - German Pomeranian (2), Terrier - Yorkshire (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (4), Vomiting (4), Behavioural disorder NOS (3), Diarrhoea (3). Outcome, 17 coded reports: Ongoing leads at 29.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.